scPharmaceuticals to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that John Tucker, president & CEO, will participate virtually in two upcoming investor conferences. The first event is the 11th Annual LifeSci Partners Corporate Access Event 2022, scheduled for January 5-7, 2022. Attendees can register and request one-on-one meetings via the provided link. The second event is the H.C. Wainwright Virtual BioConnect 2022 Conference, taking place from January 10-13, 2022, with a webcast available on-demand starting January 10 at 7am EST.

News Market Reaction – SCPH

+7.77%

+7.77% Session move

In the trading session that priced this news, SCPH gained 7.77%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, will participate virtually in two upcoming investor conferences.

Events:

11^th Annual LifeSci Partners Corporate Access Event 2022
Wednesday, January 5 – Friday, January 7
Registration and to submit 1x1 meeting requests: LifeSci Partners Corporate Access Event 2022

H.C. Wainwright Virtual BioConnect 2022 Conference
Monday, January 10 – Thursday, January 13
A webcast of Mr. Tucker’s presentation will be available on-demand as of 7am EST, Monday, January 10.

A replay of the presentation can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.

About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
ktaudvin@scpharma.com

Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
hans@lifesciadvisors.com 

FAQ

What are the upcoming investor conferences for SCPH?

John Tucker, president & CEO of scPharmaceuticals, will participate in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022, and the H.C. Wainwright Virtual BioConnect Conference from January 10-13, 2022.

When will John's presentation at H.C. Wainwright be available?

The webcast of John Tucker’s presentation will be available on-demand starting at 7am EST on January 10, 2022.

Where can I find a replay of the SCPH presentation?

A replay of the presentation can be accessed under the 'News & Events' section of scPharmaceuticals' Investor Relations website.

What is the focus of scPharmaceuticals Inc.?

scPharmaceuticals is focused on developing and commercializing products designed to reduce healthcare costs and improve health outcomes, particularly for acute conditions.